Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mark, Scalzo"'
Autor:
Shahneen Sandhu, Simon P. Keam, Scott Williams, Catherine Mitchell, Michael S Hofman, Paul J Neeson, Renu Eapen, Nathan Lawrentschuk, Price Jackson, Omar Alghazo, Arun Azad, Declan G. Murphy, Mark Scalzo, Nattakorn Dhiantravan, Daniel Moon, John Violet
Publikováno v:
European Urology Focus. 7:234-237
LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e2eb9dfb8957c5b12d80fb6205f4b93
https://doi.org/10.1016/j.euf.2020.09.021
https://doi.org/10.1016/j.euf.2020.09.021
Publikováno v:
Journal of Nuclear Medicine. 61:1030-1036
Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative approach is to take advantage of existing pharmacokinetic data from these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aebe57eb326c3c8c2ebc3accc44310ff
https://doi.org/10.2967/jnumed.119.233411
https://doi.org/10.2967/jnumed.119.233411
Autor:
David A. Pattison, Alexis Beaulieu, Shahneen Sandhu, Sue-Ping Thang, Price Jackson, Tim Akhurst, Peter Eu, Scott Williams, Declan G. Murphy, John Violet, Victor Kalff, Aravind S. Ravi Kumar, Ben Tran, Justin Ferdinandus, Christina Guo, Mark Scalzo, Michael S Hofman, Grace Kong, Rodney J. Hicks, Amir Iravani, Jennifer Mooi
Publikováno v:
Journal of Nuclear Medicine. 61:857-865
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a274455e6a3d9090bf12180a4c5772b
https://doi.org/10.2967/jnumed.119.236414
https://doi.org/10.2967/jnumed.119.236414
Autor:
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Anne Spain, Lisa Horvath, Megan Crumbaker, Angelyn Anton, Roslyn Wallace, Anupama Pasam, Mathias Bressel, Erin Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy J. Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney Hicks, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 40:5017-5017
5017 Background: The VISION and TheraP trials have established the safety and efficacy of 177Lu-PSMA-617 in mCRPC with a 50% PSA response rate (PSA50-RR) of 46% and 66% and median progression free survival (PFS) of 8.7 and 5.1 months, respectively. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::162c9bea57caad54dd2b4c22946d68ea
https://doi.org/10.1200/jco.2022.40.16_suppl.5017
https://doi.org/10.1200/jco.2022.40.16_suppl.5017
Autor:
Nattakorn, Dhiantravan, John, Violet, Renu, Eapen, Omar, Alghazo, Mark, Scalzo, Price, Jackson, Simon P, Keam, Catherine, Mitchell, Paul J, Neeson, Shahneen, Sandhu, Scott G, Williams, Daniel, Moon, Nathan, Lawrentschuk, Arun, Azad, Michael S, Hofman, Declan G, Murphy
Publikováno v:
European urology focus. 7(2)
LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8fb9967772773267a384add95fbc28cd
https://pubmed.ncbi.nlm.nih.gov/33172774
https://pubmed.ncbi.nlm.nih.gov/33172774
Autor:
Declan G. Murphy, Amir Iravani, Price Jackson, Aravind S. Ravi Kumar, Scott Williams, John Violet, Tim Akhurst, Rodney J. Hicks, Justin Ferdinandus, Shahneen Sandhu, Peter Eu, Mark Scalzo, Sue Ping Thang, Grace Kong, Michael S Hofman
Publikováno v:
Journal of Nuclear Medicine. 60:517-523
177Lu-prostate-specific membrane antigen (PSMA)-617 enables targeted delivery of β-particle radiation to prostate cancer. We determined its radiation dosimetry and relationships to pretherapeutic imaging and outcomes. Methods: Thirty patients with p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048f990bc38477f616a8509af29f8480
https://doi.org/10.2967/jnumed.118.219352
https://doi.org/10.2967/jnumed.118.219352
Autor:
John, Violet, Shahneen, Sandhu, Amir, Iravani, Justin, Ferdinandus, Sue-Ping, Thang, Grace, Kong, Aravind Ravi, Kumar, Tim, Akhurst, David A, Pattison, Alexis, Beaulieu, Jennifer, Mooi, Ben, Tran, Christina, Guo, Victor, Kalff, Declan G, Murphy, Price, Jackson, Peter, Eu, Mark, Scalzo, Scott, Williams, Rodney J, Hicks, Michael S, Hofman
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::befb53f19701961af0f77cbe3d8b9b06
https://pubmed.ncbi.nlm.nih.gov/32073970
https://pubmed.ncbi.nlm.nih.gov/32073970
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(7)
Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative approach is to take advantage of existing pharmacokinetic data from these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::88f0670ce47f31de17c09858df73f038
https://pubmed.ncbi.nlm.nih.gov/31924721
https://pubmed.ncbi.nlm.nih.gov/31924721
Autor:
Scott Williams, Shahneen Sandhu, Simon P. Keam, Daniel Moon, Michael S Hofman, Nathan Lawrentschuk, Price Jackson, Nattakorn Dhiantravan, Arun Azad, Paul J Neeson, Catherine Mitchell, Omar Alghazo, Renu Eapen, Declan G. Murphy, Mark Scalzo, John Violet
Publikováno v:
Journal of Clinical Oncology. 39:TPS264-TPS264
TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite curative intent, a significant number of men will progress with metastatic disease or local recurrence. Lutetium-177 radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69a862cf8a841159c2f15f3f93aaf666
https://doi.org/10.1200/jco.2021.39.6_suppl.tps264
https://doi.org/10.1200/jco.2021.39.6_suppl.tps264
Autor:
John, Violet, Price, Jackson, Justin, Ferdinandus, Shahneen, Sandhu, Tim, Akhurst, Amir, Iravani, Grace, Kong, Aravind Ravi, Kumar, Sue Ping, Thang, Peter, Eu, Mark, Scalzo, Declan, Murphy, Scott, Williams, Rodney J, Hicks, Michael S, Hofman
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 60(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5cb8a6407a234962e9d18f5ae987f6ed
https://pubmed.ncbi.nlm.nih.gov/30291192
https://pubmed.ncbi.nlm.nih.gov/30291192